8-K: Inotiv Cleared: SEC Concludes Investigation with No Enforcement Action Recommended

Inotiv, Inc. announced that the U.S. Securities and Exchange Commission's Division of Enforcement has concluded its investigation into the company's non-human primate importation practices and does not intend to recommend an enforcement action.

Summary

• Inotiv, Inc. (NOTV) reported that the U.S. Securities and Exchange Commission's (SEC) Division of Enforcement has concluded its investigation into the company.
• The investigation, which began with a voluntary request on May 23, 2023, focused on the company's, Envigo Global Services, Inc.'s, and Orient BioResource Center, Inc.'s importation of non-human primates from Asia.
• The SEC sought information regarding compliance with the U.S. Foreign Corrupt Practices Act (FCPA) related to these importation practices for the period from December 1, 2017, to the present.
• A formal order of investigation was provided in March 2024, dated January 9, 2024, followed by supplemental document requests on April 12, 2024.
• On June 2, 2025, Inotiv received notice that the Division of Enforcement does not intend to recommend an enforcement action against the company based on the information available.

Sentiment

Score: 8

Explanation: The conclusion of a significant SEC investigation without any recommended enforcement action is a highly positive development for the company, removing a major overhang and significantly reducing regulatory risk and uncertainty for investors.

Positives

• The SEC's Division of Enforcement has concluded its investigation into Inotiv, Inc.
• The Division does not intend to recommend an enforcement action against the company, effectively removing a significant regulatory overhang and potential for penalties.

Negatives

• The company was subject to a formal SEC investigation concerning its non-human primate importation practices and potential Foreign Corrupt Practices Act violations.
• The investigation spanned a period from December 1, 2017, to June 2, 2025, indicating prolonged scrutiny and associated legal costs.

Risks

• While the current investigation is concluded without enforcement action, the company operates in a highly regulated industry, and future regulatory scrutiny or investigations remain a possibility.
• Reputational risk associated with past investigations, even if concluded favorably, could persist among certain stakeholders.

Future Outlook

The document does not provide specific forward-looking financial guidance or strategic outlook, but the conclusion of the SEC investigation without enforcement action removes a significant regulatory uncertainty that could positively impact future operations and investor sentiment by reducing legal and compliance risks.

Management Comments

• "As previously disclosed, on May 23, 2023, Inotiv, Inc. (the Company) received a voluntary request from the U.S. Securities and Exchange Commission (the SEC) seeking documents and information for the period from December 1, 2017 to the present regarding the Company, Envigo Global Services, Inc., and Orient BioResource Center, Inc.s importation of non-human primates from Asia, including information relating to whether their importation practices complied with the U.S. Foreign Corrupt Practices Act."
• "On June 2, 2025, the SEC provided notice to the Company, through the Companys external counsel, that the SECs Division of Enforcement (the Division) has concluded its investigation and, based on the information available to the Division as of the date of its letter, the Division does not intend to recommend an enforcement action by the SEC against the Company."

Industry Context

The life sciences and contract research organization (CRO) industries, particularly those involved in animal research and global supply chains, are subject to stringent regulatory oversight, including animal welfare laws and anti-corruption statutes like the FCPA. This announcement indicates that Inotiv has successfully navigated a significant regulatory challenge related to its supply chain for non-human primates, a critical resource in preclinical research. The resolution of such investigations can reduce uncertainty for companies operating in this highly regulated space and may set a precedent for how similar issues are handled within the industry.

Legal Proceedings

• The U.S. Securities and Exchange Commission (SEC) conducted an investigation into Inotiv, Inc. regarding its importation of non-human primates from Asia and compliance with the U.S. Foreign Corrupt Practices Act.
• The SEC's Division of Enforcement has concluded this investigation and, based on available information, does not intend to recommend an enforcement action against the company.

Stakeholder Impact

• Shareholders: Reduced uncertainty and risk, potentially leading to positive share price movement as a significant regulatory overhang is lifted and future legal liabilities are avoided.
• Employees: Increased stability and clarity regarding the company's regulatory standing, potentially boosting morale.
• Customers: Reassurance regarding the company's compliance and operational integrity, which can strengthen business relationships.
• Regulators: Demonstrates the company's cooperation with regulatory bodies during investigations, potentially fostering a more favorable relationship.

Next Steps

• The company will continue its operations without the immediate threat of SEC enforcement action related to this specific investigation.
• Continued adherence to regulatory compliance, particularly regarding animal importation and anti-corruption laws, will remain crucial to prevent future scrutiny.

Key Dates

Recommendation

Keywords

Inotiv, NOTV, SEC, Investigation, Enforcement Action, Foreign Corrupt Practices Act, FCPA, Non-human Primates, Animal Research, Regulatory Compliance, Biotechnology, Pharmaceutical Services